| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ... The Lancet 389 (10066), 255-265, 2017 | 4977 | 2017 |
| Epidermal growth factor-related peptides and their receptors in human malignancies DS Salomon, R Brandt, F Ciardiello, N Normanno Critical reviews in oncology/hematology 19 (3), 183-232, 1995 | 3772 | 1995 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3755 | 2016 |
| EGFR antagonists in cancer treatment F Ciardiello, G Tortora New England Journal of Medicine 358 (11), 1160-1174, 2008 | 2726 | 2008 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2641 | 2010 |
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS … E Van Cutsem, CH Köhne, I Láng, G Folprecht, MP Nowacki, S Cascinu, ... Journal of Clinical Oncology 29 (15), 2011-2019, 2011 | 2387 | 2011 |
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1946 | 2012 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1457 | 2019 |
| A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor F Ciardiello, G Tortora Clinical Cancer Research 7 (10), 2958-2970, 2001 | 1442 | 2001 |
| Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ... Clinical Cancer Research 6 (5), 2053-2063, 2000 | 1300 | 2000 |
| Chronic inflammation and oxidative stress in human carcinogenesis A Federico, F Morgillo, C Tuccillo, F Ciardiello, C Loguercio International journal of cancer 121 (11), 2381-2386, 2007 | 1256 | 2007 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 1067 | 2016 |
| Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer E Van Cutsem, HJ Lenz, CH Köhne, V Heinemann, S Tejpar, I Melezínek, ... Journal of clinical oncology 33 (7), 692-700, 2015 | 954 | 2015 |
| Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six … D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ... Annals of oncology 28 (8), 1713-1729, 2017 | 945 | 2017 |
| Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ... JAMA oncology 3 (2), 194-201, 2017 | 837 | 2017 |
| Treatment of gastric cancer M Orditura, G Galizia, V Sforza, V Gambardella, A Fabozzi, MM Laterza, ... World journal of gastroenterology: WJG 20 (7), 1635, 2014 | 823 | 2014 |
| Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ... Clinical cancer research 7 (5), 1459-1465, 2001 | 818 | 2001 |
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ... Cancer research 62 (24), 7284-7290, 2002 | 735 | 2002 |
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer W De Roock, V De Vriendt, N Normanno, F Ciardiello, S Tejpar The lancet oncology 12 (6), 594-603, 2011 | 730 | 2011 |
| Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials C Bokemeyer, E Van Cutsem, P Rougier, F Ciardiello, S Heeger, ... European journal of cancer 48 (10), 1466-1475, 2012 | 717 | 2012 |
